Abbreviations used in this paper: CW, Calcofluor white; DSP, dithiobissuccinimidyl propionate; PAT, protein acyl transferase.

Introduction
============

The ER is an important quality control site within the cell, where proteins destined for secretion or for sorting to post-Golgi organelles are monitored for proper folding and oligomeric assembly. Proteins that fail to fold or assemble are typically retained in the ER and, in some cases, retrotranslocated to the cytoplasm for proteosomal degradation ([@bib16]). Polytopic membrane proteins receive particular scrutiny in this regard. Indeed, many diseases are attributable to the failed ER export of mutant transmembrane proteins ([@bib23]).

Yeast genetic analyses have identified several ER resident proteins that mediate the ER export of specific polytopic membrane proteins. For instance, Shr3 is required for the ER export of the yeast amino acid permeases. In *shr3Δ* mutants, these permeases are retained in the ER, whereas the transit of other polytopic proteins is unimpaired ([@bib7]). Similarly, Gsf2, Pho86, and Chs7, which are unrelated to Shr3 at the sequence level, are specifically required for the ER export of the hexose transporter Hxt1, the phosphate transporter Pho84, and the chitin synthase Chs3, respectively ([@bib10]). These export factors have been suggested either to direct the segregation of their target proteins into budding COPII vesicles for anterograde transport or, alternatively, to act as dedicated chaperones, regulating proper protein folding before transport.

The yeast chitin synthase Chs3, which is a polytopic protein with six to eight predicted transmembrane domains, provides a genetic model for understanding mechanisms of transport through the secretory pathway. Chs3-mediated chitin deposition at the plasma membrane is highly regulated at the level of intracellular trafficking. Chs3 is maintained at steady state in an intracellular pool that may correspond to the TGN or endosomes ([@bib30]), and it is transported to the plasma membrane upon activation of the *BCK1-SLT2* cell-integrity signaling pathway ([@bib29]). Mutants that impair cell wall chitin deposition have been found to block the plasma membrane delivery of Chs3 at different intracellular transport steps, whereas Chs7 mediates the ER export of Chs3, Chs5 and Chs6 direct its transport from the TGN to the plasma membrane, and Chs4 is required both for Chs3 activity at the cell surface and for its localization at the bud neck (for review see [@bib19]). We describe a genomic analysis of factors that regulate the transport of Chs3 to the cell surface, and identify an unexpected role for protein palmitoylation in the ER export of Chs3.

Palmitoylation, which is the thioester linkage of palmitate to selected cysteine residues, is one of several lipid modifications used for tethering proteins to membranes ([@bib1]). For transmembrane proteins, which are already embedded in the bilayer, the functional consequences of palmitoylation are not clear, though a role in directing segregation to membrane microdomains (lipid rafts) is often invoked. Enzymes for protein palmitoylation, which are called protein acyl transferases (PATs), were identified only recently by work in yeast ([@bib13]; [@bib21]). The first two PATs to be characterized, Akr1 and Erf2, were found to contain a conserved zinc finger--like Asp-His-His-Cys (DHHC) domain, suggesting that this motif defines a larger PAT family. Yeast has seven DHHC proteins, whereas 23 are identifiable from the human genome. More recent reports have linked additional DHHC proteins to the palmitoylation of various substrates in both yeast and mammalian cells (for review see [@bib17]). In this study, we find the uncharacterized yeast DHHC protein Pfa4 to be required for ER export by acting as the dedicated PAT for Chs3 palmitoylation.

Results and discussion
======================

Chs3 cell surface activity requires the DHHC PAT Pfa4
-----------------------------------------------------

To identify additional genes required for Chs3 trafficking, we developed a fluorescence assay suitable for the large-scale screening of yeast deletion arrays, based on the binding of the fluorescent antifungal drug Calcofluor white (CW) to cell wall chitin ([Fig. 1 A](#fig1){ref-type="fig"}; [@bib20]). Mutants that are defective for the transport of Chs3 to the cell surface produce little chitin, and thus exhibit low levels of fluorescence. We screened three independent gene-deletion collections in duplicate and calculated the median fluorescence intensity for each strain. As expected, the mutants with the lowest fluorescence values included *chs3Δ* cells, which lack chitin synthase III, and strains deleted for the known Chs3 transport factors *CHS4--7* ([Fig. 1 B](#fig1){ref-type="fig"}). In addition, the screen identified *slt2Δ* and *bck1Δ*, which are components of the cell-integrity pathway that stimulates the cell surface transport of Chs3, indicating that colony fluorescence values correlate well with independent measures of cell wall chitin ([@bib11]). Unexpectedly, cells deleted for the uncharacterized ORF YOL003c (*PFA4*) consistently displayed fluorescence values comparable to *chs3--7* mutants ([Fig. 1, B and C](#fig1){ref-type="fig"}). Pfa4 is predicted to be a 45-kD protein containing the signature DHHC cysteine-rich domain that has been linked to protein palmitoylation ([@bib1]). Like *chs* mutants, *pfa4Δ* cells not only bind less CW but are also strikingly resistant to CW toxicity ([Fig. 1 C](#fig1){ref-type="fig"}).

![**Pfa4 mutants show reduced fluorescence on CW media.** (A) Representative white light and fluorescence images showing part of a MATα yeast deletion array grown on 50 μg/ml CW. (B) Ranked list of mutants with the lowest median fluorescence values. (C) Growth and fluorescence phenotypes of wild-type (BY4741) and congenic *chs3Δ*, *chs6Δ*, *chs7Δ*, and *pfa4Δ* cells on 75 μg/ml CW. F, fluorescence; WL, white light.](jcb1740019f01){#fig1}

Pfa4 is required for the ER exit of Chs3
----------------------------------------

To determine if the low levels of cell wall chitin in *pfa4Δ* mutants result from alterations in the intracellular transport of Chs3, we examined the subcellular localization of Chs3-GFP in *pfa4Δ* strains and in mutants with known Chs3-trafficking defects. In wild-type cells, Chs3-GFP is present at the bud neck, bud tip, and intracellular compartments, whereas it is completely restricted to this latter compartment in *chs6Δ* mutants, which is consistent with a mislocalization to the TGN or endosomes ([Fig. 2 A](#fig2){ref-type="fig"}; [@bib31]). In contrast, Chs3-GFP localized to intracellular rings in *pfa4Δ* mutants, which are similar to those seen in *chs7Δ* mutants, where ER exit of Chs3 is blocked ([@bib27]). Colocalization with the ER marker Sec61 confirmed that Chs3-GFP resided primarily in the ER of *pfa4Δ* cells ([Fig. 2 B](#fig2){ref-type="fig"}); however, unlike *chs7Δ* cells, a small proportion of cells also showed some Chs3-GFP at the bud neck or bud tip. The ER-localized pool of Chs3 is not unstable or targeted for degradation, as Chs3 is present at wild-type levels in *pfa4Δ* mutants ([Fig. 2 C](#fig2){ref-type="fig"}). These results indicate that loss of cell surface Chs3 activity in *pfa4Δ* mutants results from a defect in transport at the ER. Moreover, this transport defect is specific to Chs3, as localization of other yeast chitin synthases, Chs1 and Chs2, are unaltered in *pfa4Δ* cells ([Fig. 2 D](#fig2){ref-type="fig"}).

![**Chs3-GFP mislocalizes to the ER in *pfa4Δ* cells.** (A) Wild-type (KLY9), *chs6Δ* (KLY1), *chs7Δ* (KLY3), and *pfa4Δ* (KLY5) cells expressing Chs3-GFP were observed by differential interference contrast and fluorescence microscopy. (B) *Chs3*-GFP colocalizes with the ER-marker Sec61-RFP in *pfa4Δ* (KLY55) cells. (C) Chs3-3xHA levels in wild-type (KLY41) and *pfa4Δ* (KLY43) cells, as shown by Western blotting with α-HA mAb. α-PGK1 was used as a loading control. (D) Localization of Chs1- and Chs2-GFP in wild-type and *pfa4Δ* cells. Bars, 2 μm.](jcb1740019f02){#fig2}

Chs3 is palmitoylated in a Pfa4-dependent manner
------------------------------------------------

Because Pfa4 is a predicted PAT, we considered the possibility that ER export of Chs3 requires a Pfa4-mediated palmitoylation event. For the few DHHC PATs examined to date, mutation of the cysteine within the core DHHC tetrapeptide element has been found to abolish PAT activity both in vivo and in vitro ([Fig. 3 A](#fig3){ref-type="fig"}; [@bib13]; [@bib21]; [@bib25]; [@bib28]). Therefore, cysteine108 within the Pfa4 DHHC sequence was mutated to alanine. The Pfa4^DHHA^ mutant protein accumulated to wild-type levels ([Fig. 3 B](#fig3){ref-type="fig"}), indicating that the substitution does not destabilize Pfa4. Nevertheless, plasmid-borne *pfa4^DHHA^* failed to complement CW resistance and Chs3-GFP mislocalization in *pfa4Δ* mutants ([Fig. 3, C and D](#fig3){ref-type="fig"}), suggesting these phenotypes are caused by a lack of Pfa4 enzymatic activity. Deletion of other DHHC proteins did not alter CW fluorescence ([Fig. 3 E](#fig3){ref-type="fig"}).

![**The DHHC domain of Pfa4 is required for Chs3 localization.** (A) Topology of the four characterized yeast DHHC proteins (Akr1, Erf2, Swf1, and Pfa3) and Pfa4. ANK, ankyrin repeats; black boxes, hypothetical transmembrane domains; Zf-DHHC, zinc finger--like DHHC cysteine-rich domain. (B) Western blots of lysates prepared from *pfa4Δ* cells carrying plasmids expressing Pfa4-3xHA, Pfa4^DHHA^-3xHA, or vector alone indicate the DHHA mutant is stably expressed in vivo. α-Vph1 mAb was used as a loading control. (C) Serial dilutions of strains from B on 100 μg/ml CW. (D) *pfa4Δ* strains expressing Chs3-GFP (KLY5) were transformed with empty vector, p*PFA4*, or p*PFA4* ^DHHA^, and observed by microscopy. Bar, 2 μm. (E) Fluorescence phenotype of mutants lacking other DHHC proteins on 75 μg/ml CW. F, fluorescence; WL, white light.](jcb1740019f03){#fig3}

To determine if Chs3 is the direct target of Pfa4, we tested Chs3 for palmitoylation using a modified acyl-biotin exchange assay ([@bib5]; [@bib18]). This three-step protocol involves the following: (1) blockade of free thiols with N-ethylmaleimide, (2) hydroxylamine cleavage of palmitoylation thioester linkages, and (3) thiol-specific biotinylation of the newly exposed cysteinyl thiols. To control for acyl-biotin exchange specificity, samples omitting the key hydroxylamine cleavage step were processed in parallel. We found that Chs3 is palmitoylated, and this modification is Pfa4-dependent, being abolished in *pfa4Δ* and *pfa4^DHHA^* mutants ([Fig. 4 A](#fig4){ref-type="fig"}). In contrast, palmitoylation of the other chitin synthases, Chs1 and Chs2, or the ER export factor Chs7, could not be detected (unpublished data). Other PATs have been shown to copurify with their substrates ([@bib9]). Pfa4--Chs3 complexes could be detected by coimmunoprecipitation ([Fig. 4 B](#fig4){ref-type="fig"}), suggesting that Pfa4 interacts directly with Chs3 to mediate its palmitoylation. The observation that Chs3 is ER-localized and palmitoylated in *chs7Δ* cells ([Fig. 4 C](#fig4){ref-type="fig"}) is consistent with Chs3 palmitoylation being an early, ER-localized event.

![**Pfa4 is required for palmitoylation of Chs3.** (A) Lysates from cells expressing C-terminally 3xHA-FLAG epitope-tagged Chs3 from the *GAL1* promoter were subjected to the acyl-biotin exchange reactions. Protein extracts were treated with (+) or without (−) hydroxylamine (NH~2~OH). α-FLAG immunoprecipitates were blotted with α-biotin and α-HA to detect modified and total Chs3, respectively. (B) Cells expressing Chs3-GFP and Pfa4-3xHA were immunoprecipitated with α-HA antiserum and analyzed by Western blotting with α-HA and α-GFP mAbs. (C) Chs3 palmitoylation was assessed in wild-type, *pfa4Δ*, and *chs7Δ* cells by acyl exchange, as in A. (D) Coimmunoprecipitation of Chs3-GFP and Pfa4-3xHA in wild-type and *chs7Δ* cells as performed in B.](jcb1740019f04){#fig4}

To date, four of the seven yeast DHHC proteins have been shown to mediate protein palmitoylation in various cellular locations ([@bib13]; [@bib21]; [@bib8]; [@bib25]; [@bib28]). Our finding of Pfa4-dependent palmitoylation for Chs3 adds a fifth DHHC protein to this list. Two other yeast PATs, Erf2/4 and Swf1, are also known to function at the ER, but recognize distinct substrates. The emerging picture is, thus, of a family of PATs that are distinguished from one another both by intracellular localization and by substrate specificity.

A requirement for palmitoylation and chaperone association in Chs3 ER export
----------------------------------------------------------------------------

As both Chs7 and Pfa4 are required for Chs3 ER export, we considered the possibility that these two proteins act together. Heterooligomeric PATs have been identified that require binding partners for activity and stability ([@bib13]). Although Chs3 palmitoylation was reduced in *chs7Δ* cells, it clearly was not abolished ([Fig. 4 C](#fig4){ref-type="fig"}). Furthermore, Chs3 copurifies with its PAT even in the absence of Chs7 ([Fig. 4 D](#fig4){ref-type="fig"}), whereas Pfa4--Chs7 interactions could not be detected under similar conditions (not depicted). Therefore, Chs7 does not appear to be required for substrate recognition by Pfa4 and is unlikely to be a subunit of a dimeric PAT.

We tested an alternative model, in which Chs7 preferentially interacts with lipid-modified Chs3 to promote its interaction with the COPII vesicle-budding machinery ([@bib7]). Although a Chs3--Chs7 physical interaction has not been yet reported, other polytopic yeast proteins, including Gap1 and the vacuolar H-ATPase, have been shown to interact with dedicated accessory factors at the ER during biosynthesis ([@bib7]; [@bib15]). Using coimmunoprecipitation, we demonstrated that Chs3 and Chs7 do interact ([Fig. 5 A](#fig5){ref-type="fig"}, lane 3). In *pfa4Δ* cells, the Chs3--Chs7 interaction was subtly reduced, but not eliminated ([Fig. 5 A](#fig5){ref-type="fig"}, lane 2), indicating that Chs3 palmitoylation is not required for recognition by Chs7.

![**Loss of *PFA4* causes Chs3 aggregation in the ER.** (A) Cells expressing Chs3-3xHA and Chs7-GFP were subjected to immunoprecipitation with α-HA antiserum and analyzed by Western blotting with α-HA and α-GFP mAbs. Strains used were KLY46 (lanes 1 and 5), KLY45 + pTM15 (lanes 2 and 6), KLY46 + pTM15 (lanes 3 and 7), and KLY14 + pTM15 (lanes 4 and 8). (B) Lysates of wild-type, *chs7Δ*, and *pfa4Δ* cells transformed with plasmid-borne Chs3-3xHA (pHV7) were cross-linked using increasing concentrations of DSP; DTT was added to duplicate samples to reverse cross-links. Chs3 was detected by Western blotting with α-HA mAb. M, monomer; A, aggregates. (C) Cross-linking of chromosomally encoded Chs3-3xHA in wild-type (KLY41; ⋄), *chs7Δ* (KLY46; ▵), *pfa4Δ* (KLY43; □), and *chs7Δ* *pfa4Δ* (KLY45; ○) strains was performed as for B. Disappearance of monomeric Chs3 as a function of cross-linker concentration was quantified by densitometry.](jcb1740019f05){#fig5}

Chs3 aggregates in the absence of Pfa4
--------------------------------------

Recent work has suggested a chaperone function for Chs7 and the ER accessory proteins Shr3, Gsf2, and Pho86 ([@bib10]). When their cognate chaperones were absent, the substrate polytopic proteins were found to accumulate in the ER in high molecular mass aggregates, which were visualized by cross-linking with dithiobissuccinimidyl propionate (DSP). Using the DSP cross-linking protocol of [@bib10], we examined Chs3 aggregation in *pfa4Δ* cells ([Fig. 5 B](#fig5){ref-type="fig"}). Chs3-HA was readily cross-linked into high molecular mass forms in *chs7Δ*, *pfa4Δ*, and *chs7Δ* *pfa4Δ* mutants ([Fig. 5, B and C](#fig5){ref-type="fig"}), indicating that Chs7 chaperone function and Pfa4-mediated palmitoylation are both required to circumvent Chs3 aggregation.

Despite the similarity of the *chs7Δ* and *pfa4Δ* phenotypes, our data do not support models that Chs7 and Pfa4 act together as part of a complex or linear pathway. Instead, our results are best accommodated by models where Chs7 and Pfa4 act in parallel, mediating separate events that are both required for ER export. Nonetheless, defects in one pathway do appear to affect the other; Chs3 palmitoylation is reproducibly reduced in *chs7Δ* cells, and the Chs3--Chs7 interaction is decreased in *pfa4Δ* cells.

As both Chs7 and Pfa4 are required to circumvent Chs3 accumulation in high molecular mass aggregates, both appear to participate in the prerequisite folding of Chs3 that precedes ER export. Hydrophobic mismatch, resulting from an incompatibility between long transmembrane domains of polytopic proteins and the thinner ER bilayer, could explain why a membrane protein such as Chs3 requires both palmitoylation and chaperone association for export. ER chaperones have been hypothesized to shield hydrophobic regions of transmembrane domains to prevent protein aggregation ([@bib12]). Palmitoylation may also promote hydrophobic matching by targeting proteins to cholesterol-rich membrane microdomains, which provide a local region of higher bilayer thickness. It is interesting that Chs1 and Chs2, which are also polytopic proteins, require neither Chs7 nor Pfa4 for ER export. This suggests a requirement for chaperone association and palmitoylation for only a subset of membrane proteins.

Several recent results suggest that the palmitoylation requirement for ER export may not be unique to Chs3. Our concurrent proteomic analysis of yeast protein palmitoylation indicates that several amino acid permeases are palmitoylated in a Pfa4-dependent manner ([@bib22]). Intriguingly, these polytopic proteins also require dedicated accessory proteins for their ER export ([@bib10]). It will be interesting to see if, as for Chs3, palmitoylation plays a role in permease trafficking. The link between palmitoylation and ER exit may hold true for at least some polytopic proteins in higher cells, as it was recently reported that functional cell surface expression of the nicotinic acetylcholine receptor requires an ER palmitoylation event ([@bib6]). Thus, palmitoylation may participate more generally in ER quality control mechanisms, particularly for newly synthesized polytopic integral membrane proteins.

Materials and methods
=====================

General molecular biology methods were as previously described ([@bib2], [@bib3]). Primer sequences are available on request. Protein topologies were predicted by the Simple Modular Architecture Research Tool (<http://smart.embl-heidelberg.de/>).

CW genomic screen
-----------------

Three yeast knockout collections (in strain backgrounds BY4741, BY4742, and BY4743) were obtained from Open Biosystems and pinned four times in 1,536-array format onto YPD plates containing 50 μg/ml CW (Sigma-Aldrich), using a Virtek automated colony arrayer (Bio-Rad Laboratories). After incubation at 30°C for 3 d, white-light images were acquired using a flat-bed scanner (model 2400; Epson), and fluorescent-light images were captured with a Fluor S Max MultiImager (Bio-Rad Laboratories) using the 530DF60 filter and Quantity One software (version 4.2.1; Bio-Rad Laboratories). The open-source spot-finding program GridGrinder (<http://gridgrinder.sourceforge.net>) was used for the densitometry of digital images. Average growth and fluorescence values from two independent screens were calculated for each strain using Excel (Microsoft); slow-growing strains were removed from the analysis.

Strain construction
-------------------

The BY4741 (*MAT*a *his3Δ* *1 leu2Δ* *0 met15Δ* *0 ura3Δ* *0*) knockout strains *akr1Δ*, *akr2Δ*, *chs3Δ*, *chs6Δ*, *chs7Δ*, *erf2Δ*, *pfa3Δ*, *pfa4Δ*, *pfa5Δ*, and *swf1Δ* and the BY4742 (*MAT*α *his3Δ* *1 leu2Δ* *0 lys2Δ* *0 ura3Δ* *0)* knockout strains *chs7Δ* and *pfa4Δ* used in this study were obtained from Open Biosystems. Deletion mutants used for palmitoylation assays were in the BY4742 background. Other strains are listed in [Table I](#tbl1){ref-type="table"}.

###### 

**Yeast strains used in this study**

  Strain   Genotype
  -------- ---------------------------------------------------------
  KLY1     BY4741 *chs6*∷kan^R^ *CHS3*-GFP∷*HIS3*
  KLY3     BY4741 *chs7*∷kan^R^ *CHS3*-GFP∷*HIS3*
  KLY5     BY4741 *pfa4*∷kan^R^ *CHS3*-GFP∷*HIS3*
  KLY9     BY4741 *CHS3*-GFP∷*HIS3*
  KLY14    BY4741 *chs7*∷*HIS3*
  KLY41    BY4741 *CHS3*-3xHA∷kan^R^
  KLY43    BY4741 *pfa4*∷nat^R^ *CHS3*-3xHA∷kan^R^
  KLY45    BY4741 *chs7*∷*HIS3 pfa4*∷nat^R^ *CHS3*-3xHA∷kan^R^
  KLY46    BY4741 *chs7*∷*HIS3 CHS3*-3xHA∷kan^R^
  KLY55    BY4741 *pfa4*∷kan^R^ *CHS3*-GFP∷*HIS3 SEC61*-RFP∷*URA3*
  KLY60    BY4741 *CHS1*-GFP∷*HIS3*
  KLY62    BY4741 *CHS2*-GFP∷*HIS3*
  KLY65    BY4741 *CHS2*-GFP∷*HIS3 pfa4*∷nat^R^
  KLY66    BY4741 *CHS1*-GFP∷*HIS3 pfa4*∷nat^R^
  KLY67    BY4741 *chs7*∷kan^R^ *pfa4*∷nat^R^ *CHS3*-GFP∷*HIS3*

KLY14 was created by transforming a 3.5-kb EcoRV fragment from pTM10 ([@bib4]) into wild-type BY4741. To create KLY45, a nat^R^ cassette amplified from p4339 ([@bib26]) using primers with flanking homology to 5′ and 3′ *PFA4* sequences was transformed into KLY14. C-terminal tags (GFP and 3xHA) were integrated at the *CHS3* locus as previously described ([@bib14]). C-terminal tagging of *SEC61* with RFP was performed as previously described ([@bib24]).

Plasmid construction
--------------------

A PCR fragment containing *PFA4*-3xHA was created using a two-step PCR method ([@bib2]) and cotransformed into *pfa4Δ* yeast together with XhoI-cut pRS415 or XhoI-cut pRS426, thereby creating pKL1 and pKL3, respectively. Plasmids were rescued and tested for complementation of *pfa4Δ* CW resistance phenotypes and expression of Pfa4-3xHA by Western blotting. pKL6 was created by QuikChange (Stratagene) mutagenesis of pKL1, using primers designed to change Cys108 to alanine. The resulting mutant was confirmed by sequencing. For construction of pND2115, which is *GAL1*-CHS3-3xHA-FLAG-His carried on pRS316, the *CHS3* ORF was PCR amplified from yeast genomic DNA and was used to replace the *AKR1* ORF of a *GAL1*-AKR1-3xHA-FLAG-His plasmid construct ([@bib21]). pHV7 (*CHS3*-3xHA), pTM10 (*chs7*∷*HIS3*; [@bib4]), and pTM15 (*CHS7*-GFP; [@bib27]) were gifts from C. Roncero (Universidad de Salamanca, Salamanca, Spain).

Microscopy
----------

For fluorescence microscopy of GFP- or RFP-tagged strains, log-phase cells grown in minimal media were observed directly. Indirect immunofluorescence microscopy was performed as previously described ([@bib2], [@bib3]). For DAPI staining, cells were mounted in buffered glycerol containing 1 mg/ml p-phenylenediamine and 0.05 μg/ml DAPI. Cells were viewed using a 100× oil-immersion objective on a fluorescence microscope (Axioplan2; Carl Zeiss MicroImaging, Inc.), and images were captured with a camera (CoolSNAP; Roper Scientific) using MetaMorph 6.2r6 software (Molecular Devices). Images were adjusted for brightness with Photoshop CS2 (Adobe).

Cross-linking
-------------

Cross-linking of yeast cell lysates with DSP was performed as previously described ([@bib10]) with slight modifications. DSP was added to 10 μg of protein in 40 μL PBS. Reactions were quenched with 40 mM Tris HCl, pH 7.5, at 25°C for 30 min. Parallel samples were treated with 40 mM DTT at 37°C for 30 min.

Palmitoylation assay
--------------------

Chs3 palmitoylation was assessed by acyl-biotinyl exchange ([@bib18]), using a modified version of the Drisdel and Green method ([@bib5]). Denatured protein extracts, which were prepared from Chs3-3xHA-FLAG-His--expressing cells (2-h galactose-induced expression period) by glass-bead lysis, were subjected to the three steps of acyl-biotinyl exchange protocol, as previously described ([@bib18]). The epitope-tagged Chs3 was immunoprecipitated with M2 anti-FLAG-agarose, and then Western blotted with either anti--biotin-HRP or anti--HA-HRP.

Coimmunoprecipitations
----------------------

Coprecipitation was performed as previously described ([@bib2]). 20 OD~600~ of spheroplasts were resuspended in 1 mL lysis buffer (1% CHAPSO, 50 mM KPO~4~, pH7.5, 50 mM NaCl, and protease inhibitors) and incubated with 3 μL of rabbit α-HA antiserum for 1 h at 4°C. 30 μL of protein G--Sepharose (GE Healthcare) was added for 1 h at 4°C. Beads were washed twice in lysis buffer and subjected to SDS-PAGE. Coimmunoprecipitated proteins were analyzed by Western blotting with antibodies to HA or GFP.
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